Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

14
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
14
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

19
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual Patient Data Validation of the EAU Definitions of BCG Failure in Patients with Non-muscle-invasive Urothelial Carcinoma of the Bladder: An International Multicenter Retrospective Study.

European urology oncology·2026
Same author

Impact of intravesical BCG Therapy on quality of life in non-muscle-invasive bladder cancer: a prospective evaluation using the FACT-Bl questionnaire.

Actas urologicas espanolas·2026
Same author

Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group.

Actas urologicas espanolas·2026
Same author

Novel risk factors for venous thromboembolism following outpatient or inpatient transurethral resection of bladder tumors: Multivariable stepwise and LASSO regression modeling from us insurance claim database.

Actas urologicas espanolas·2025
Same author

Impact of opium on bladder cancer incidence: A systematic review and meta-analysis.

Actas urologicas espanolas·2025
Same author

Real-life perception of pathology reports in urology.

Actas urologicas espanolas·2025

Related Experiment Video

Updated: Aug 20, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).

Y Neuzillet1, B Pradère2, E Xylinas3

  • 1Service d'Urologie, hôpital Foch, Université Paris Saclay, Suresnes, France.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|November 18, 2022
PubMed
Summary

Updated guidelines for non-muscle-invasive bladder cancer (NMIBC) management improve diagnosis and treatment. These recommendations focus on risk stratification and tailored adjuvant therapies for better patient outcomes.

Keywords:
BCGBladderBladder tumoursCancerCarcinome urothélialCystectomieCystectomyCytologie urinaireSurvieSurvivalTumeurs de la vessieUrine cytologyUrothelial carcinomaVessie

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.8K

Related Experiment Videos

Last Updated: Aug 20, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.8K

Area of Science:

  • Urology
  • Oncology

Background:

  • Non-muscle-invasive bladder cancer (NMIBC) requires updated management strategies.
  • Accurate diagnosis and risk stratification are crucial for effective NMIBC treatment.

Approach:

  • A systematic literature review (2020-2022) evaluated diagnosis, treatment, and surveillance of NMIBC.
  • Evidence levels were assessed to inform updated clinical practice guidelines.

Key Points:

  • Complete tumor resection is essential for NMIBC diagnosis (Ta, T1, CIS).
  • Bladder fluorescence and second-look procedures enhance diagnostic accuracy.
  • The EORTC score aids in assessing recurrence and progression risk.
  • Risk stratification (low, intermediate, high) guides adjuvant therapies like intravesical chemotherapy or BCG instillations.
  • Cystectomy is considered for BCG-resistant cases.

Conclusions:

  • Updated ccAFU recommendations aim to optimize patient management for NMIBC.
  • Improved diagnostic and therapeutic approaches are expected to enhance NMIBC care.